U.S. flag

An official website of the United States government

NM_000190.4(HMBS):c.636G>A (p.Met212Ile) AND not provided

Germline classification:
Uncertain significance (2 submissions)
Last evaluated:
Jan 18, 2022
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001056264.11

Allele description [Variation Report for NM_000190.4(HMBS):c.636G>A (p.Met212Ile)]

NM_000190.4(HMBS):c.636G>A (p.Met212Ile)

Gene:
HMBS:hydroxymethylbilane synthase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
11q23.3
Genomic location:
Preferred name:
NM_000190.4(HMBS):c.636G>A (p.Met212Ile)
HGVS:
  • NC_000011.10:g.119092148G>A
  • NG_008093.1:g.12272G>A
  • NM_000190.4:c.636G>AMANE SELECT
  • NM_001024382.2:c.585G>A
  • NM_001258208.2:c.636G>A
  • NM_001258209.2:c.585G>A
  • NP_000181.2:p.Met212Ile
  • NP_001019553.1:p.Met195Ile
  • NP_001245137.1:p.Met212Ile
  • NP_001245138.1:p.Met195Ile
  • LRG_1076t1:c.636G>A
  • LRG_1076t2:c.585G>A
  • LRG_1076:g.12272G>A
  • LRG_1076p1:p.Met212Ile
  • LRG_1076p2:p.Met195Ile
  • NC_000011.9:g.118962858G>A
  • NM_000190.3:c.636G>A
Protein change:
M195I
Links:
dbSNP: rs1219587773
NCBI 1000 Genomes Browser:
rs1219587773
Molecular consequence:
  • NM_000190.4:c.636G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001024382.2:c.585G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001258208.2:c.636G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001258209.2:c.585G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001220698Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Jul 13, 2021)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV002549477GeneDx
criteria provided, single submitter

(GeneDx Variant Classification Process June 2021)
Uncertain significance
(Jan 18, 2022)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001220698.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This variant is not present in population databases (ExAC no frequency). This variant has been observed in an individual affected with clinical features of porphyria (Invitae). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant disrupts the p.Met212 amino acid residue in HMBS. Other variant(s) that disrupt this residue have been observed in individuals with HMBS-related conditions (PMID: 10602775), which suggests that this may be a clinically significant amino acid residue. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces methionine with isoleucine at codon 212 of the HMBS protein (p.Met212Ile). The methionine residue is moderately conserved and there is a small physicochemical difference between methionine and isoleucine.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From GeneDx, SCV002549477.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024